Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Nyrada (ASX:NYR) Rallies Following New Preclinical Oncology Data

Nyrada Inc (ASX:NYR) shares climbed 13.51% to AUD 0.63 during the afternoon session on 20 May 2026 after the biotechnology company released favourable preclinical oncology study results involving its lead drug candidate, Xolatryp. The stock has also recorded a substantial gain of approximately 472.73% …

Aditi Sarkar | 20 May 2026

Mach7 Technologies (ASX:M7T) Surges on New US Contract and Faster SaaS Deployment

Mach7 Technologies (ASX:M7T) is an Australia-listed healthcare technology company specializing in enterprise imaging software solutions. Its core platform enables healthcare providers to store, access, and share diagnostic imaging data across complex and often fragmented healthcare systems.

Sonal Goyal | 20 May 2026

OncoSil Medical (ASX:OSL) Shares Skyrocket ~54% Today- Here's Why?

OncoSil Medical Ltd (ASX:OSL) shares recorded a sharp rally during the morning session on 20 May 2026 after the company announced that it had received approval from Australia’s Therapeutic Goods Administration (TGA) for its OncoSil device.

Aditi Sarkar | 20 May 2026

EBR Systems (ASX:EBR) Advances U.S. Rollout with CHRISTUS Health Agreement

EBR Systems Inc (ASX:EBR) shares moved higher during the morning session on 20 May 2026 after the company announced a new purchasing agreement with CHRISTUS Health, one of the largest hospital networks in the United States.

Aditi Sarkar | 20 May 2026

Cleo Diagnostics (ASX:COV) Gains as U.S. Commercialisation Plans Advance

Cleo Diagnostics Ltd (ASX:COV) shares traded modestly higher during the morning session on 20 May 2026 after the company announced a key step in its United States commercialisation strategy ahead of its anticipated Food and Drug Administration (FDA) submission.

Aditi Sarkar | 20 May 2026

Nyrada (ASX:NYR) Shares Climb Following Key Regulatory Milestone

Nyrada Inc (ASX:NYR) shares increased 2.78% to AUD 0.56 on 19 May 2026 after the biotechnology company announced a favourable intellectual property development linked to its lead drug candidate, Xolatryp. The stock has also delivered a notable gain of more than 404% over the …

Aditi Sarkar | 19 May 2026

Amplia Therapeutics (ASX:ATX) Remains Flat Despite Key Trial Milestone

Amplia Therapeutics Ltd (ASX:ATX) announced the launch of the first stage of a new Phase 2b study evaluating narmafotinib in advanced pancreatic cancer, marking another step in the Company’s effort to progress the therapy toward a potential registrational pathway. Despite the clinical development update …

Aditi Sarkar | 19 May 2026

This ASX Healthcare Stock Jumps Following International Collaboration Deal

Invion Limited (ASX:IVX) shares moved higher during the afternoon session on 19 May 2026 after the Company announced a new collaboration agreement with South Korean ophthalmic solutions company SANGMYUNG Innovation Co., Ltd. The agreement expands Invion’s Photosoft platform technology into ophthalmology, with an initial …

Aditi Sarkar | 19 May 2026

Micro-X (ASX:MX1) Shares Back in Focus After DHS Funding Extension

Micro-X Limited (ASX:MX1) has announced a new funding extension tied to its U.S. airport security initiative, with the company securing an additional AUD 1.3 million (US$0.9 million) contract extension from the U.S. Department of Homeland Security (DHS). The extension will support continued development of …

Aditi Sarkar | 19 May 2026

4DMedical (ASX:4DX) Advances Precision Lung Care With New Clinical Validation

4DMedical Limited (ASX:4DX) has announced a new clinical milestone for its CT:VQ platform following the publication of a peer-reviewed study in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), widely regarded as one of the leading journals in respiratory medicine globally. The …

Aditi Sarkar | 19 May 2026
Support

Hi! How can we help you today?

Loading…